PharmaBlock (USA), Inc. recently completed renovation of its new process R&D center in Philadelphia Suburbs, co-located with products distribution and custom service center. As Phase I of the PharmaBlock Pennsylvania site, the 7000 sq ft facility has successfully brought together several experienced process chemists from major pharmaceutical companies, and is now in fully operation. Phase II is scheduled to be operated starting from next year, doubling the existing lab space of the facility. The laboratories are set up to support PharmaBlock’s growth in supplying pharmaceutical intermediates and APIs to North American customers.
PharmaBlock (USA), Inc. is a subsidiary of PharmaBlock Sciences (Nanjing), Inc., a leading innovative chemistry products and services provider throughout the pharmaceutical R&D process. The company opened its first USA facility in the Bay Area of California in 2012, and established USA headquarters in Pennsylvania in late 2017. “Combining our expertise in pharmaceutical process research and unique collections of pharmaceutical building blocks, the new research center will encourage new technologies and innovation, and strength our position in meeting growing demand for early development API.” Said Dr. Jing Li, President of PharmaBlock (USA), Inc.
Building on its success of supplying novel building blocks at lab-scale, PharmaBlock has been establishing top notch process R&D capabilities during the past years. Its Process R&D Center based in China has applied many new technologies, including biocatalysis, flow chemistry, photochemistry, and fluorination, in a lot of challenging pharmaceutical intermediates and APIs. The expansion of the Process R&D laboratory in the United States will continue the strategy PharmaBlock has followed since completing its IPO at the end of 2017.